Citation Impact
Citing Papers
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Child abuse: Adolescent records vs. adult recall
1990 Standout
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
2010
Osteoporosis
2019 Standout
Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
2013
Osteonecrosis of the Jaw in a Patient on Denosumab
2010
Osteonecrosis of the jaw – Prevention and treatment strategies for oral health professionals
2013
NF-κB signaling in inflammation
2017 Standout
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Breast cancer
2016 Standout
Thyroid cancer
2016 Standout
RANK/RANKL: Regulators of Immune Responses and Bone Physiology
2008
Cancer to bone: a fatal attraction
2011 Standout
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial
2010
Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
2014
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Skeletal-Related Events due to Bone Metastases from Differentiated Thyroid Cancer
2012
NF-κB, the first quarter-century: remarkable progress and outstanding questions
2012 Standout
Unravelling the complexity of metastasis — molecular understanding and targeted therapies
2011
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Metastatic Cancer Identified in Osteonecrosis Specimens of the Jaws in Patients Receiving Intravenous Bisphosphonate Medications
2013
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Pathogenesis of myeloma bone disease
2008
Secondary Causes of Osteoporosis
2012
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Osteoporosis: now and the future
2011 Standout
Bone cancer pain: Causes, consequences, and therapeutic opportunities
2013
Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions
2010
Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials
2014
Breast Cancer Metastasis
2013
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
2011
Acute kidney injury
2019 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Epidemiology and pathogenesis of osteonecrosis of the jaw
2011
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
2013
Bone health in cancer patients: ESMO Clinical Practice Guidelines
2014
Bladder cancer
2016 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
2011
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
2011
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
2008
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Role of NF-κB in the skeleton
2010
Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials
2013
Targeting metastasis
2016
Cancer immunotherapy comes of age
2011 StandoutNature
Antiresorptives and Osteonecrosis of the Jaw
2012
Microenvironmental regulation of metastasis
2008 Standout
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Targeting tumor–stromal interactions in bone metastasis
2013
Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis
2011
Future directions of bone-targeted therapy for metastatic breast cancer
2010
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
2009
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling
2011 Nature
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases
2008
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Effects of Bone-Targeted Agents on Cancer Progression and Mortality
2012
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study
2012
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Skeletal and extraskeletal actions of denosumab
2012
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
2012
The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
2009
Novel approaches to target the microenvironment of bone metastasis
2021
Bisphosphonate conjugation for bone specific drug targeting
2018
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
2012
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis
2012
Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
2017 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Osteosarcoma
2010
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure
2009
Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference
2008
Pain regulation by non-neuronal cells and inflammation
2016 StandoutScience
Periapical Disease and Bisphosphonates Induce Osteonecrosis of the Jaws in Mice
2013
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
2010
Approach to the Thyroid Cancer Patient with Bone Metastases
2011
Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions
2010
Nephrotoxicity of anticancer treatment
2016
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Guidelines for the management of thyroid cancer
2014 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
2008
Works of Susie Jun being referenced
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
2008
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 Standout
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
2012
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
2013
RANKL inhibition in the treatment of bone metastases
2008
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
2012
An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma
2009
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
2010
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
2011
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
2009
Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
2008
Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases
2007